文献速递类风湿关节炎

类风湿关节炎与甲氨蝶呤对妊娠结局的影响:意大利风湿病学会回顾性队列研究

Impact of rheumatoid arthritis and methotrexate on pregnancy outcomes: retrospective cohort study of the Italian Society for Rheumatology.
PubMed 文献 · RMD Open · 2022-01-01

基于意大利行政医疗数据库的回顾性队列研究,纳入3564例接受或未接受甲氨蝶呤治疗的类风湿关节炎患者及14256例无类风湿关节炎对照。接受甲氨蝶呤治疗的患者妊娠丢失风险显著高于无类风湿关节炎女性(OR 2.22,95%CI 1.40-3.45),且孕前3个月内暴露于甲氨蝶呤与选择性终止妊娠风险显著正相关(OR 4.77,95%CI 1.08-19.40)。作者认为需加强孕前咨询以避免非计划妊娠。

要点

  • 接受甲氨蝶呤治疗的类风湿关节炎患者妊娠丢失风险显著高于无类风湿关节炎女性(OR 2.22,95%CI 1.40-3.45)。
  • 孕前3个月内暴露于甲氨蝶呤与选择性终止妊娠风险显著正相关(OR 4.77,95%CI 1.08-19.40)。
  • 三队列妊娠比例分别为6.3%、9.1%和11.9%,先天性畸形在所有队列中均极罕见。

核心结论

  • 接受甲氨蝶呤治疗的患者似乎是妊娠丢失风险最高的队列。
  • 孕前3个月内暴露于甲氨蝶呤与选择性终止妊娠的正相关关系,强化了进行充分孕前咨询以避免非计划妊娠的必要性。

研究设计与样本

  • 回顾性队列研究,基于行政医疗数据库开展。
  • 纳入三个育龄女性队列:第一队列为2004年7月至2011年12月期间开始甲氨蝶呤治疗的类风湿关节炎患者;第二队列为同一人群中随机选取的未接受甲氨蝶呤治疗的类风湿关节炎患者(比例1:1);第三队列为无类风湿关节炎的受试者(比例1:4)。
  • 两个匹配的类风湿关节炎队列共纳入3564例接受和未接受甲氨蝶呤治疗的患者;无类风湿关节炎队列纳入14256例受试者。
  • 采用多因素逻辑回归模型,报告OR及95%CI。

主要发现

  • 三个队列中随访期间实现妊娠的女性比例分别为6.3%、9.1%和11.9%。
  • 先天性畸形在所有队列中均极罕见。
  • 任何时间孕前接受甲氨蝶呤治疗的类风湿关节炎女性,妊娠丢失风险显著高于无类风湿关节炎女性(OR 2.22,95%CI 1.40-3.45)。
  • 孕前3个月窗口内暴露于甲氨蝶呤与选择性终止妊娠风险增加存在显著正相关(OR 4.77,95%CI 1.08-19.40)。

关键数值与推荐

  • 接受甲氨蝶呤治疗的类风湿关节炎女性与无类风湿关节炎女性相比,妊娠丢失的OR为2.22(95%CI 1.40-3.45)。
  • 孕前3个月窗口内暴露于甲氨蝶呤与选择性终止妊娠的OR为4.77(95%CI 1.08-19.40)。

临床怎么用

  • 原文结论未据此给出具体临床推荐,仅指出需进行充分孕前咨询以避免非计划妊娠。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of rheumatoid arthritis (RA) and methotrexate (MTX) on the probability of becoming pregnant, pregnancy losses, elective termination of pregnancy (TOP) and congenital malformations. METHODS: A retrospective cohort study on administrative healthcare databases was conducted. Three patients' cohorts were enrolled among childbearing-age women. The first cohort included patients with RA starting MTX between July 2004 and December 2011. The second cohort included patients with RA without MTX treatment randomly selected from the same population (ratio 1:1). Finally, a cohort of subjects without RA was identified (ratio 1:4). Multivariate logistic regression models were implemented, ORs and 95% CI were reported. RESULTS: The two matched RA cohorts included 3564 patients with MTX and without MTX. The cohort without RA included 14 256 subjects. In the three cohorts, the proportion of women achieving pregnancy during follow-up was 6.3%, 9.1% and 11.9%, respectively. Congenital malformations were very rare in all cohorts. RA women treated with MTX at any time before conception showed significantly higher risks of pregnancy losses than non-RA women (OR (95% CI) 2.22 (1.40 to 3.45)). We observed a significant positive relationship between the exposure to MTX in the 3 months window before conception and increased risk of elective TOP (OR (95% CI) 4.77 (1.08 to 19.40)). CONCLUSION: MTX-treated patients appeared to be the cohort with the highest risk of pregnancy losses. The positive association with elective TOP and exposure to MTX in the three months window before conception in patients with RA reinforces the need for adequate preconception counselling to avoid unplanned pregnancies.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Zanetti A, Zambon A, Scirè CA, et al. Impact of rheumatoid arthritis and methotrexate on pregnancy outcomes: retrospective cohort study of the Italian Society for Rheumatology. RMD Open. 2022. PMID: 36597979. doi:10.1136/rmdopen-2022-002412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。